Showing results (1561-1570 of 4,521) with videos related to

Sort By:
Pageof 453
Future Oncology (London, England)|November 21, 2019
Incidence and survival trends for appendiceal mucinous adenocarcinoma: an analysis of 3237 patients in the Surveillance, Epidemiology, and End Results databaseQian Yan, Wenjiang Zheng, Huiyan Luo, et al.
Future Oncology (London, England)|November 6, 2019
Value assessment of immuno-oncology in the treatment of rare tumors in the era of accelerated conditional approvalsTereza Lanitis, Apoorva Ambavane, Ying Zheng, et al.
Future Oncology (London, England)|December 17, 2019
First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysisRavi B Parikh, Emily K Feld, Matthew D Galsky, et al.
Future Oncology (London, England)|December 18, 2019
Different prognostic significance of examined lymph node count for patients with non-small-cell lung cancer ≤1 cm or >1-2 cm: a population-based studyZhen Liang, Xiaohang Wang, Heli Yang, et al.
Future Oncology (London, England)|December 19, 2019
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivityAntonio Frassoldati, Laura Biganzoli, Roberto Bordonaro, et al.
Future Oncology (London, England)|December 21, 2019
Experience with eribulin in pretreated patients with advanced liposarcoma: a case seriesAnna Paioli, Elisabetta Setola, Emanuela Palmerini, et al.
Future Oncology (London, England)|December 25, 2019
Dedifferentiated liposarcoma: when eribulin can make the differenceAndrea Sbrana, Federico Paolieri, Francesco Bloise, et al.
Future Oncology (London, England)|February 26, 2020
Primary lymph node sites in Hodgkin lymphoma and the risk of second primary cancers: a population-based studyAmr Ebied, Muawia Yousif, Nguyen Hai Nam, et al.
Future Oncology (London, England)|February 28, 2020
Nutritional outcomes after radiotherapy target volume reduction for nasopharyngeal cancer: a Phase III trialLi Xiang, Jin-Feng Rong, Hao-Wen Pang, et al.
Future Oncology (London, England)|March 14, 2020
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemiaPau Montesinos, Benjamin M Beckermann, Olivier Catalani, et al.
Pageof 453